Dutch Competition Body Urged To Fine Leadiant Over 'Exorbitant' Orphan Drug Price

 
• By Ian Schofield
  
SC1711_Purse-Pills_673872868_1200
Leadiant is accused of charging too much for its CTX drug
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access